A Phase 3 interventional study of Sonelokimab in Arthritis, Psoriatic, sponsored by MoonLake Immunotherapeutics AG. Enrolling by invitation at 18 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by MoonLake Immunotherapeutics AG · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Arthritis, Psoriatic with a site in United States — 29 open to participants now, 59 under way, 20 of them phase 3. Arthritis, Psoriatic · United States.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, this one is the 4th largest by planned enrollment of the 158 interventional ones that give a count, is one of 14 that started in 2025, is one of 71 in phase 3, reaches primary completion later than 42 of the 58 other live ones, and was the 184th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.
Browse Arthritis, Psoriatic studies →29 of the 193 studies in Arthritis, Psoriatic with a site in United States are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of Texas Southwestern Medical Center · Sites in United States
Ages 18–65
Medical College of Wisconsin · Sites in United States
Ages 18+
Takeda · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 35 · Phase 3 73 · Phase 4 18
First in 1991; this study’s year is marked. 14 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,560 is above the median of 145 across 336 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 237 across the 158 interventional studies, 325 across the 34 observational. Of the 128 that completed or were terminated, 79 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
129 of 193 have an industry lead sponsor. The 10 most frequent:
MoonLake Immunotherapeutics AG is the lead sponsor of 10 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.
MoonLake Immunotherapeutics AG has 4 studies filed under Arthritis, Psoriatic — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Psoriatic with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06641089Phase 3MoonLake Immunotherapeutics AGEvaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | 2027-01-04 |
| NCT06807424Phase 3Janssen Research & Development, LLCA Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis | 2027-02-10 |
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
| NCT06671483Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | 2027-05-18 |
| NCT06671496Phase 3TakedaA Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | 2027-05-18 |
Add all 16 to your calendar (.ics) → With an account.
Among the 193 studies in Arthritis, Psoriatic with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)
M1095-PSA-303 is a Phase 3, multicenter, open-label extension study to investigate the long-term safety, tolerability and clinical efficacy of sonelokimab 60 mg subcutaneously every 4 weeks in patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants will receive sonelokimab subcutaneously every 4 weeks
Drug: Sonelokimab
Open-label
Long-term safety and tolerability of sonelokimab:
Treatment-emergent adverse events (TEAEs)
Time frame: 52 weeks
Long-term safety and tolerability of sonelokimab:
Serious adverse events (SAEs)
Time frame: 52 weeks
Long-term safety and tolerability of sonelokimab:
TEAEs leading to study withdrawal
Time frame: 52 weeks
Long-term safety and tolerability of sonelokimab:
Adverse events of special interest (AESIs)
Time frame: 52 weeks
Long-term safety and tolerability of sonelokimab:
Clinically significant changes in vital signs and standard 12-lead electrocardiogram Measure description: Number of participants with clinically significant changes in vital signs and 12-lead ECG intervals from baseline
Time frame: 52 weeks
Long-term safety and tolerability of sonelokimab:
Clinically significant changes in clinical laboratory parameters Measure description: Number of participants with clinically significant changes in hematology, biochemistry and urinalysis from baseline
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Proportion of participants achieving American College of Rheumatology (ACR) 20/50/70% improvement criteria over time
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Change over time in Minimal disease activity (MDA)
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Change over time in Health assessment questionnaire-disability index (HAQ-DI)
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Change over time in Tender joint count (TJC)68/ swollen joint count (SJC)66
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Proportion of participants achieving Psoriasis Area and Severity Index (PASI) 75/90/100 over time
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Change over time in Modified Nail Psoriasis Severity Index (mNAPSI)
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Proportion of participants achieving Very low disease activity (VLDA) over time
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Proportion of participants achieving SpondyloArthritis Research Consortium of Canada (SPARCC) over time
Time frame: 52 weeks
Long-term efficacy of sonelokimab:
Change over time in Leeds Enthesitis Index (LEI)
Time frame: 52 weeks
Long term efficacy of sonelokimab
Proportion of participants achieving both an ACR 50/ACR70 and PASI90/100 improvement over time
Time frame: 52 weeks
Started Nov 2025 (actual). Primary completion is estimated for Feb 2028, 26 months after the start.
Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 26 months is close to that.
Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonelokimab
MoonLake Immunotherapeutics AG